journal article·2022-11-11

Gelatin-Based Injectable Hydrogel/Microgel Composite as a Combinational Dual Drug Delivery System for Local Co-delivery of Curcumin and 5-Fluorouracil in Synergistic Therapy of Colorectal Cancer

Sarvenaz Pakian, Fatemeh Radmanesh, Hamid Sadeghi-Abandansari, Mohammad-reza Nabid

ACS Applied Polymer Materials· Volume 4· Issue 11
Publisher page

Abstract

Chemotherapy using curcumin (Cur) and 5-fluorouracil (5-FU) has been broadly applied to treat colorectal cancer (CRC). In situ chemotherapy mediated by biological macromolecule platforms, such as gelatin-based injectable hydrogels, has recently attracted sizable attention due to their injectability, biocompatibility, and high therapeutic efficacy. Here, a microgel-embedded and micelle-cross-linked injectable hydrogel composite (MMHC) was synthesized for combinational local delivery of 5-FU and curcumin. The hydrophobic core of Pluronic-based micelles in injectable hydrogel was prepared for loading curcumin as a hydrophobic drug. The microgels were physically entrapped into the injectable hydrogel for sustained hydrophilic drug delivery. 5-FU release could be sustained for more than a month from these composite hydrogels, which is considerably longer than that achievable using the microgels alone. The proliferation inhibitory effect and cell cycle arrest were observed in HT-29 cells using the dual drug loaded MMHC system. In conclusion, the Cur/5-FU@MMHC system is a synergistic therapeutic delivery system that can achieve prolonged, sustained-release action for the combination of 5-FU and curcumin against the human colon cancer cell line HT-29.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Polymer and Materials Chemistry, Faculty of Chemistry & Petroleum Sciences, Shahid Beheshti University, 19839-63113 Tehran, Iran

Uro-Oncology Research Center, Tehran University of Medical Sciences, 14166-34793 Tehran, Iran

Department of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, 16656-59911 Tehran, Iran

Department of Cancer Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Isar 11, 47138-18983 Babol, Iran

Funding

Royan Institute

References (48)

Show source-provided references
1. 10.3390/ijms1801019710.3390/ijms18010197 ↗
2. 10.1200/JCO.2004.10.01210.1200/JCO.2004.10.012 ↗
3. 10.1016/j.phrs.2007.07.00110.1016/j.phrs.2007.07.001 ↗
4. 10.3390/biology1009085410.3390/biology10090854 ↗
5. 10.1016/j.biopha.2021.11128510.1016/j.biopha.2021.111285 ↗
6. 10.1093/bib/bbw10410.1093/bib/bbw104 ↗
7. 10.1159/00009023810.1159/000090238 ↗
8. 10.1124/jpet.118.25578610.1124/jpet.118.255786 ↗
9. 10.1016/j.phymed.2021.15354710.1016/j.phymed.2021.153547 ↗
10. 10.3390/biomedicines909108610.3390/biomedicines9091086 ↗
11. 10.1089/jmf.2013.008610.1089/jmf.2013.0086 ↗
12. 10.1007/s11655-018-2997-z10.1007/s11655-018-2997-z ↗
13. 10.1186/s11658-021-00301-910.1186/s11658-021-00301-9 ↗
14. 10.1093/carcin/bgv00610.1093/carcin/bgv006 ↗
15. 10.1093/carcin/21.2.33110.1093/carcin/21.2.331 ↗
16. Medicine U. S. N. L. o. clinicaltrials.gov. January 18, 2020. https://clinicaltrials.gov/ct2/show/NCT02724202 (accessed 2021-12-19).
17. 10.3390/molecules2416300510.3390/molecules24163005 ↗
18. 10.1038/509S69a10.1038/509S69a ↗
19. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
20. 10.1016/j.cej.2020.12827810.1016/j.cej.2020.128278 ↗
21. 10.1016/j.biomaterials.2018.08.04410.1016/j.biomaterials.2018.08.044 ↗
22. 10.1021/acs.biomac.7b0113310.1021/acs.biomac.7b01133 ↗
23. 10.1016/j.jconrel.2020.12.00810.1016/j.jconrel.2020.12.008 ↗
24. 10.1557/mrc.2017.9210.1557/mrc.2017.92 ↗
25. 10.30476/TIPS.2019.81604.100210.30476/TIPS.2019.81604.1002 ↗
26. 10.3390/jfb901001310.3390/jfb9010013 ↗
27. 10.1016/j.ijpharm.2006.03.03210.1016/j.ijpharm.2006.03.032 ↗
28. 10.1016/j.eurpolymj.2021.11064610.1016/j.eurpolymj.2021.110646 ↗
29. 10.1021/bm201170h10.1021/bm201170h ↗
30. 10.1021/acsami.8b0439410.1021/acsami.8b04394 ↗
31. 10.1016/j.biomaterials.2005.08.01310.1016/j.biomaterials.2005.08.013 ↗
32. 10.1002/mabi.20080031710.1002/mabi.200800317 ↗
33. 10.1039/c4ra00788c10.1039/c4ra00788c ↗
34. 10.1039/C4TC00877D10.1039/C4TC00877D ↗
35. 10.1088/1758-5082/6/2/02500610.1088/1758-5082/6/2/025006 ↗
36. 10.1039/c0nr00758g10.1039/c0nr00758g ↗
37. 10.1016/j.colsurfb.2011.08.01010.1016/j.colsurfb.2011.08.010 ↗
38. War A. R. · J. Cancer Res. · 2018 · 4 · 1000117
39. 10.1186/s11671-019-2909-y10.1186/s11671-019-2909-y ↗
40. Kurečič M. · Materiali in tehnologije · 2012 · 46 · 87
41. 10.1016/j.addr.2012.09.01310.1016/j.addr.2012.09.013 ↗
42. 10.1039/C1SM06513K10.1039/C1SM06513K ↗
43. 10.1039/C4PY01415D10.1039/C4PY01415D ↗
44. 10.1039/C7PY00161D10.1039/C7PY00161D ↗
45. Gerweck L. E. · Cancer Res. · 1996 · 56 · 1194
46. 10.1039/c0sm01393e10.1039/c0sm01393e ↗
47. 10.7150/thno.5626610.7150/thno.56266 ↗
48. 10.1038/nrc107410.1038/nrc1074 ↗